跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NT-12
首页
药物
NT-12
NT-12
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
REMEDIES FOR NERVE DAMAGES
US 2007243160 A1
申请人: INST OF GENE AND BRAIN SCIENCE
优先权: 2001
US
2 件公开
Pharmaceutical compositions comprising metal complexes
US 2002049190 A1
申请人: BRIDGER GARY J
优先权: 2000
US
18 human secreted proteins
EP 1471072 A1
申请人: HUMAN GENOME SCIENCES INC
优先权: 2000
EP
Super-agonistic anti-CD-28 antibodies
EP 2497829 A1
申请人: THERAMAB LLC
优先权: 2005
EP
Composite antibacterial peptide produced by bacillus natto NT-6 and production method thereof
CN 102321182 A
申请人: UNIV GUANGDONG OCEAN
优先权: 2011
CN
Applications of targeted HOTAIR-inhibiting small RNA in preparation of anti-prostate cancer drugs
CN 104971363 A
申请人: UNIV ZHEJIANG
优先权: 2015
CN
Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by a synthetic ligand or arginylated BIP binding to the P62 ZZ domain
US 10391067 B2
申请人: SEOUL NAT UNIV R&DB FOUNDATION
优先权: 2015
US
Controllable DNA self-assembly immunostimulation system and application thereof
CN 118634242 A
申请人: NAT CT NANOSCIENCE & TECHNOLOGY CHINA
优先权: 2024
CN
COMBINATION THERAPIES FOR METABOLIC DISEASE
WO 2026035744 A1
申请人: CEDARS SINAI MEDICAL CENTER
优先权: 2024
WO
一种靶向CAIX和FAP的化合物、其核素标记物、制法和应用
CN 119119174 B
申请人: 重庆医科大学附属第二医院
优先权: 2024
CN
第 1 / 2 页
上一页
下一页
药物
反馈